Ki67 Immunostaining in Primary Breast Cancer
Author Information
Author(s): N. Bouzubar, K.J. Walker, K. Griffiths, I.O. Ellis, C.W. Elston, J.F.R. Robertson, R.W. Blamey, R.I. Nicholson
Primary Institution: Tenovus Institute for Cancer Research, University of Wales College of Medicine
Hypothesis
Does Ki67 immunostaining correlate with clinical and pathological features in primary breast cancer?
Conclusion
Ki67 immunostaining is a useful marker for assessing cell proliferation in breast cancer and is associated with early recurrence after mastectomy.
Supporting Evidence
- 54% of the examined tumours were positive for Ki67 binding.
- Ki67 positivity was significantly associated with histological grade of malignancy.
- Patients with Ki67 positive tumours had a less favorable early prognosis.
Takeaway
This study looked at a special test called Ki67 that helps doctors see how fast breast cancer cells are growing. It found that higher levels of Ki67 can mean the cancer might come back sooner after treatment.
Methodology
The study involved immunostaining of Ki67 in 136 primary breast cancer specimens and correlating the results with clinical and pathological features.
Limitations
The study was limited to a single center and followed patients for a maximum of 18 months.
Participant Demographics
Patients were unselected primary breast cancer patients undergoing mastectomy.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website